Beneficial Ownership Report · SCHEDULE 13G
Polyrizon Ltd.
PLRZNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- Polyrizon Ltd.
- Company CIK
- 0001893645
- Street
- 8 Ha-Pnina Street
- City
- Raanana
- State / country code
- L3
- Postal code
- 4321545
Statement details
- Security class
- Ordinary Shares
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- Armistice Capital, LLC
- Citizenship / organization
- DE
- Reporting person type
- IA · OO
- Aggregate amount owned
- 208,000.00
- Percent of class
- 8.32
- Sole voting power
- 0.00
- Shared voting power
- 208,000.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 208,000.00
- Aggregate excludes certain shares
- N
Reporting person 2
- Name
- Steven Boyd
- Citizenship / organization
- X1
- Reporting person type
- HC · IN
- Aggregate amount owned
- 208,000.00
- Percent of class
- 8.32
- Sole voting power
- 0.00
- Shared voting power
- 208,000.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 208,000.00
- Aggregate excludes certain shares
- N
Item 1
Issuer
Polyrizon Ltd.
Principal executive office address
8 Ha-Pnina Street, Raanana, 4321545, Israel
Item 2
Citizenship
Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
Filing person
Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
Principal business or residence address
Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
Item 3
Not applicable indication
N
Type of filing person
IA · HC
Item 4
Percent of class
8.32%
Amount beneficially owned
208,000
Sole voting power
0
Shared voting power
208,000
Sole dispositive power
0
Shared dispositive power
208,000 Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: November 16, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd
Signature 1
- Reporting person
- Armistice Capital, LLC
- Signed
- /s/ Steven Boyd
- Title
- Steven Boyd - Managing Member
- Date
- 11/16/2026
Signature 2
- Reporting person
- Steven Boyd
- Signed
- /s/ Steven Boyd
- Title
- Steven Boyd
- Date
- 11/16/2026
Company context
We are a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Our proprietary Capture and Contain™, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. We are further developing certain aspects of our proprietary C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. We refer to our separate platform technology that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T.